HomeQURE • NASDAQ
add
Uniqure NV
Previous close
$17.99
Day range
$17.10 - $19.22
Year range
$7.76 - $71.50
Market cap
1.14B USD
Avg Volume
4.59M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 5.57M | 6.65% |
Operating expense | 15.55M | 306.77% |
Net income | -37.09M | 49.38% |
Net profit margin | -666.06 | 52.53% |
Earnings per share | — | — |
EBITDA | -47.19M | -26.81% |
Effective tax rate | 9.55% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 622.54M | 69.39% |
Total assets | 824.91M | 48.22% |
Total liabilities | 626.01M | 11.13% |
Total equity | 198.90M | — |
Shares outstanding | 62.37M | — |
Price to book | 5.64 | — |
Return on assets | -14.64% | — |
Return on capital | -16.77% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -37.09M | 49.38% |
Cash from operations | — | — |
Cash from investing | -441.37M | -1,557.79% |
Cash from financing | — | — |
Net change in cash | -516.75M | -457.14% |
Free cash flow | -82.10M | -62.23% |
About
uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies. Wikipedia
CEO
Founded
1998
Website
Employees
221
